1 Result: Neuronetics
Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
May 09th, 2023
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69. Meanwhile, Voyager Therapeutics. Read more
Want To Find Some News?
Recent Post
-
NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025Earnings Preview: Amicus Therapeutics, ANSYS, and Etsy Take Center Stage
February 16th, 2025Key Metrics: Walmart, Booking Holdings, and Insmed Earnings Due
February 16th, 2025
Member Login